Objective To study the efficacy and safety of TACE combined with imatinib mesylate in hepatic metasta-ses of gastrointestinal stromal tumors. Methods Twenty-six patients with advanced hepatic metastases of gastrointestinal stro-mal tumors were treated by single TACE ( control group ), other nineteen patients were treated by imatinib mesylate combination with TACE ( experimental group ). The therapeutic effect, survival rates and median survival of two groups were compared. Results The effective rate of the experimental group was 78. 9% , significantly higher than that in the control group ( 69. 2% , P <0. 05 ). The survival rates in 1, 2 and 3 years were 69. 2% , 53. 8% and 19. 2% ,respectively, with a mediansurvival time of 1. 72 years in the control group, and 84. 2% , 73. 7% and 47. 4% , respectively, with a median survival time of 2. 1 years in experimental group. The survival rates and median survival time in the experimental group were significantly improved than those of the control group ( P < 0. 05 ). Conclusion It suggested that the TACE combined with imatinib mesy-late was a safe and effective therapy strategies for patients with advanced hepatic metastases of gastrointestinal stromal tumors.%目的 观察甲磺酸伊马替尼(格列卫)联合肝动脉化疗栓塞术(TACE)治疗胃肠间质瘤(GIST)肝转移的疗效及安全性.方法 选取26例中晚期胃肠间质瘤肝转移的患者仅行TACE治疗(对照组),同时选取19例中晚期胃肠间质瘤肝转移的患者,给予格列卫口服联合TACE治疗(观察组),比较2组患者的临床疗效和生存率、中位生存期.结果 观察组有效率为78.9%,明显高于对照组的69.2%(P<0.05);对照组患者1、2、3年生存率分别为69.2%、53.8%和19.2%,中位生存期1.72年;观察组患者1、2、3年生存率分别为84.2%、73.7%和47.4%,中位生存期2.10年.观察组的生存率及生存期均显著高于对照组(P<0.05).结论 格列卫联合TACE治疗晚期胃肠间质瘤肝转移疗效及安全性优于仅行TACE治疗.
展开▼
